AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03352973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active tDCS on the dlPFC
Description: During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
Study NCT03352973 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS on the dlPFC
Description: During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
Study NCT02758132 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
Study NCT02758132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg enzalutamide by mouth daily
Study NCT02758132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: 1000 mg abiraterone by mouth daily
Study NCT01367912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol tablet
Description: received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
Study NCT01367912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol tablet
Description: received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
Study NCT04087746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
Study NCT04087746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intra-vitreal injection of AVEGF Ranibizumab in group 2
Study NCT03762330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPD structured self-management plan.
Description: Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
Study NCT03601507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO
Study NCT03601507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03601507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies
Study NCT03601507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01765413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella-zoster virus
Study NCT01765413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Study NCT01765413 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03505060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA CON-S env
Description: Administered by intramuscular injection in the deltoid.
Study NCT03505060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IHV01
Description: Administered by intramuscular injection in the deltoid.
Study NCT03505060 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
Study NCT02758132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg prednisone by mouth twice daily
Study NCT02285647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant - Oral
Description: Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
Study NCT02285647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant - IV
Description: IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
Study NCT04172623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-Time Smoking Intervention
Description: Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
Study NCT04172623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Adult smokers will receive standard outpatient tobacco treatment.
Study NCT04172623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Adult smokers will receive standard outpatient tobacco treatment.
Study NCT04066647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: 1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
Study NCT04001933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPOP Intervention
Description: The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
Study NCT04962620 — intervention group
Intervention type: DRUG
Intervention: Bovhyaluronidase azoximer
Description: Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.
Study NCT02007616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-action video game training
Description: Based on cognitive training Lumosity
Study NCT02167425 — intervention group
Intervention type: OTHER
Intervention: IMAT
Description: The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
Study NCT00357357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HF0220
Description: comparison of different dosages of drug
Study NCT02846545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
Study NCT02846545 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to golimumab.
Study NCT02231632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Poliomyelitis vaccine (Human Diploid Cell)
Description: 6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
Study NCT02231632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)
Description: 6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
Study NCT03055182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation program
Description: Patients participate during 4 weeks to a physical rehabilitation program.
Study NCT04935281 — intervention group
Intervention type: OTHER
Intervention: percutaneous repair with an intraoperative assisted ultrasound
Description: Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
Study NCT04935281 — intervention group
Intervention type: OTHER
Intervention: percutaneous repair without an intraoperative assisted ultrasound
Description: For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
Study NCT01069016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral nerve modulation
Description: For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
Study NCT01069016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation
Description: For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
Study NCT02651467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)
Description: 1.5% w/w KOX, 0ppm F, pH 7.0
Study NCT02651467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)
Description: 2.0% w/w KOX, 45ppm F, pH 4.5
Study NCT02651467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )
Description: 0% w/w KOX 0ppm F, pH 4.5
Study NCT01031381 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RAD001
Description: RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
Study NCT01031381 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bevacizumab
Description: bevacizumab will be administered intravenously (IV) once every 14 days.
Study NCT00334685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine + Pregabalin
Description: \[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Study NCT00334685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
Study NCT01999153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mL topically used during alginate dressing NAROPEINE
Description: 20 mL topically used during alginate dressing
Study NCT01999153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 20 mL topically used during alginate dressing NaCl
Description: 20 mL topically used during alginate dressing
Study NCT03349931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction and detection of Aspergillus fumigatus in serum samples
Description: Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
Study NCT00810914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine epidural
Description: bupivicaine continuous epidural infusion
Study NCT00810914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine epidural infusion patient epidural
Description: bupivicaine
Study NCT00810914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine
Description: patient controlled anesthesia only
Study NCT01315964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plant stanol ester
Description: 3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
Study NCT01315964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant stanol ester
Description: 3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
Study NCT00590850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF with Plate and Screws
Description: ORIF with plate and screws
Study NCT00590850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pin Fixation
Description: Clavicle fixation with clavicle pin
Study NCT00111982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liatermin
Description: Liatermin
Study NCT03564431 — intervention group
Intervention type: DEVICE
Intervention: Magnetic resonance
Description: magnetic resonance spectrum of brain
Study NCT00904397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm®
Description: Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
Study NCT00904397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
Study NCT02624960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accucinch Implant
Description: Percutaneous implantation of the Accucinch Implant in the mitral subannular space
Study NCT02995031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)
Study NCT02995031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT02884882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Emotional induction
Description: Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
Study NCT02884882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emotional induction
Description: Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
Study NCT03278756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive control training
Description: 10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
Study NCT03278756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control training
Description: 10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
Study NCT03683160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Augmented Mobility Program
Description: CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
Study NCT03253575 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CANscript
Description: CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
Study NCT04524806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stabilization splint
Description: Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
Study NCT02029001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg BID)
Description: Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
Study NCT02029001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg QD)
Description: Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
Study NCT02029001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg BID)
Description: Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
Study NCT02029001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg QD)
Description: Patients whose tumor harbors mutations or amplifications of HER2
Study NCT02029001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg QD)
Description: Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT\* or amplification /translocation of the genes and/or of the ligands.
Study NCT02029001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg BID)
Description: ATM, BAP1 et BRIP1 Mutation only if double hit documented; BRCA2, BRCA1, RAD51C, PALB2, RAD51D Mutation; BRCA1, BRCA2, ATM and BAP1 Loss; BRCA1, BRCA2, ATM and BAP 1 : mutation and heterozygote deletion. except for patients eligible to olaparib's available labels and reimbursements in France.~NOTE : only prostate cancer with RECIST 1.1 evaluable disease are eligible until the French price and reimbursement
Study NCT02029001 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Description: Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
Study NCT01823146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin spray
Description: single dose of 24 IU oxytocin, self-administered intranasally (IN)
Study NCT01823146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
Study NCT02552784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: data assessment of the state of health and quality of life of patients and their families
Description: Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.